Sign up Australia
Proactive Investors - Run By Investors For Investors
Why invest in IMM?
ImmuPharma PLC: THE INVESTMENT CASE

ImmuPharma says 90% of patients have pass six-month milestone on key lupus trial

In all 200 suffers were recruited to the trial and all of them have now past the three month stage.
ImmuPharma says 90% of patients have pass six-month milestone on key lupus trial
INVESTMENT OVERVIEW: IMM The Big Picture
The first trial data will emerge early next year - the drug's safety record has been consistently robust

ImmuPharma PLC (LON:IMM) said more than 90% of the patients on its phase III clinical study of Lupuzor, for the autoimmune disease lupus, six months through the process.

In all 200 suffers were recruited to the trial and all of them have now past the three month stage.

A total of 46 patients, or just under a quarter, have completed the year-long assessment, while 40% have passed nine-months.

ImmuPharma said it remains on track to provide top-line results in the first quarter of next year.

The data was provided ahead of an investor update to be held in London that will be coupled with the company’s annual meeting later Friday.

“As the trial continues to progress, we are delighted to observe the continuation of our robust safety record, as Lupuzor is being administered to greater numbers of patients over a longer period of time,” chairman Tim McCarthy said

Big potential market

Systemic Lupus Erythematosus (SLE) is a debilitating and painful disease, which sees the body's immune system turn against itself for reasons still not fully understood.

It can affect various organs in various people in various ways so many symptoms can ensue, which calls for treatment from heart, liver and skin specialists.

It is much more common in women, appears most often in African-Americans, Asians and Hispanics and it is estimated that up to five million individuals worldwide may be affected.

ImmuPharma does not claim Lupuzor is a cure but hopes it will offer significant relief to sufferers such that their quality of life is greatly improved.

It also thought to be more effective than other products available, such as Glaxo's Benlysta. 


Ian_55ae0ddd437b7.jpg


Register here to be notified of future IMM Company articles
View full IMM profile View Profile

ImmuPharma PLC Timeline

Related Articles

Cancer highlighted
July 10 2017
The collaboration will see PDS Biotechnology Corp and a subsidiary of Merck & Co Inc embark on a new clinical trial collaboration for metastatic head and neck cancer
The Hydroponics Company Ltd issued a cannabis research licence
July 11 2017
The licence allows Canndeo to build its exclusive Plant Breeders Rights.
Patient undergoing radiotherapy
August 02 2017
Nanoparticles with mega potential - that’s how the biotech team at American investment bank described the company's technology

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use